Autres langues CSL Limited OTC Markets

Actions

CSLLY

US12637N2045

Produits pharmaceutiques

Temps Différé OTC Markets 20:18:07 08/10/2026			Varia. 5j.	Varia. 1 janv.
31,47 ^USD	-0,13%		+1,71%	+9,27%

07/10	L’accord conclu par CSL avec Alentis est à faible risque mais présente un potentiel limité, selon RBC Capital Markets	MT
07/10	Point sectoriel de la Bourse australienne (ASX) à la mi-séance : les valeurs de la santé progressent, le secteur des matériaux en difficulté	MT

Autres langues

15:06	Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027
07/10	CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says
07/10	ASX Midday Sector Update: Healthcare Stocks Advance, Materials Sector Struggles
07/10	CSL Prices $1.5 Billion in Corporate Bonds
06/10	CSL's Alentis Licensing Deal Likely to Lead to Total Addressable Market of Up to Nearly $2 Billion per Year, Jefferies Says
05/10	Global markets live: Goldman Sachs, Eli Lilly, Foxconn, Accenture, BT Group…
05/10	Morning Meeting: La política y la IA mantienen en vilo a los mercados
05/10	Australian shares edge higher as CSL deal lifts healthcare stocks
05/10	Australian Shares Flat; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug
05/10	Swiss stocks - Factors to watch on October 5
05/10	Australian shares rise as commodity-linked stocks advance
05/10	ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug
05/10	CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug
05/10	CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
04/10	CSL to Develop Kidney, Liver Disease Treatment With Alentis Therapeutics
04/10	CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
04/10	CSL And Alentis Therapeutics Announce Global Partnership To Develop And Commercialise Lixudebart For Rare Kidney And Liver Diseases
04/10	Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billion
01/10	US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere season
29/09	Amazon Web Services to Supply AI, Cloud Tech to CSL
29/09	CSL Partners With Amazon Web Services
29/09	Australia's CSL taps Amazon's cloud unit to boost research pipeline
29/09	CSL : and AWS collaborate to advance biopharmaceutical R&D
22/09	Csl Canada Expands Public Access to Andembry® Across Canada for the Prevention of Hereditary Angioedema Attacks
22/09	Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks